Tue. 9 Apr 2024, 7:06am ET
Benzinga
News
- MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resistance mechanism
- Validation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biopsies to assess target engagement of OTX-2002, our lead clinical-stage epigenomic controller